JZP-815 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JZP-815’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JZP-815 is under development for the treatment of solid tumors including non-small cell lung cancer and colorectal cancer and hematological malignancies (blood cancer). It is administered through oral route in the form of capsule. It acts by targeting pan-Raf. The drug candidate is developed based on Redox Switch platform technology.
Jazz Pharmaceuticals overview
Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
For a complete picture of JZP-815’s drug-specific PTSR and LoA scores, buy the report here.